Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Baxter
Fuji
Chinese Patent Office
Cantor Fitzgerald
Fish and Richardson
Johnson and Johnson
Farmers Insurance
Merck

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,003,679

« Back to Dashboard

Summary for Patent: 8,003,679
Title:Use of inhibitors of the renin-angiotensin system
Abstract: Inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia, such as stroke.
Inventor(s): Montgomery; Hugh Edward (London, GB), Martin; John Francis (London, GB), Erusalimsky; Jorge Daniel (London, GB)
Assignee: ArkTherapeutics Group, plc (London, GB)
Application Number:11/441,648
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,003,679

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim MICARDIS telmisartan TABLET;ORAL 020850-002 Nov 10, 1998 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OR PREVENTION OF STROKE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,003,679

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,604,070 Use of inhibitors of the renin-angiotensin system ➤ Try a Free Trial
7,071,183 Use of inhibitors of the renin-angiotensin system ➤ Try a Free Trial
7,998,953 Use of inhibitors of the renin-angiotensin system ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,003,679

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1300 ➤ Try a Free Trial
Austria 294579 ➤ Try a Free Trial
Austria 366110 ➤ Try a Free Trial
Australia 742506 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Covington
Julphar
AstraZeneca
Farmers Insurance
Accenture
Fuji
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.